BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henning A, Andreasson J. Preventing, producing, or reducing harm? Fitness doping risk and enabling environments. Drugs: Education, Prevention and Policy. [DOI: 10.1080/09687637.2020.1865273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Mcveigh J, Bates G. Stigma and the Use of Anabolic Androgenic Steroids by Men in the United Kingdom. Drugs, Identity and Stigma 2022. [DOI: 10.1007/978-3-030-98286-7_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ainsworth NP, Thrower SN, Petróczi A. Two sides of the same coin: A qualitative exploration of experiential and perceptual factors which influence the clinical interaction between physicians and Anabolic-Androgenic Steroid using patients in the UK. Emerging Trends in Drugs, Addictions, and Health 2022;2:100033. [DOI: 10.1016/j.etdah.2022.100033] [Reference Citation Analysis]
3 Havnes IA, Muller AE. Nonprescribed androgen use among women and trans men. Curr Opin Endocrinol Diabetes Obes 2021;28:595-603. [PMID: 34709214 DOI: 10.1097/MED.0000000000000680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Heuberger JAAC, Henning A, Cohen AF, Kayser B. Dealing with doping. A plea for better science, governance and education. Br J Clin Pharmacol 2021. [PMID: 34291479 DOI: 10.1111/bcp.14998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]